OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo- controlled trial in adult females

Written By Sebastian De Beurs
Sebastian De Beurs
Previous

Effects of botulinum toxin type a on mood and cognitive function in patients with parkinson’s disease and depression
Next

Treatment of Major Depressive Disorder Using Botulinum Toxin A: A 24-Week Randomized, Double-Blind, Placebo-Controlled Study